Diagnosis of the main problems in the field of intellectual resources management in pharmacy
DOI:
https://doi.org/10.24959/uekj.18.6Keywords:
intellectual resources, intellectual property, pharmacy, innovative drugsAbstract
In the conditions of innovative pharmacy development the problem of theoretical and scientific-practical approaches to intellectual resources management of drug developers and manufacturers becomes of a particular urgency.
Aim. To diagnose the main problems in the field of intellectual resources management in pharmacy and to identify the reserves for improving the efficiency of their use.
Materials and methods. In the context of our future work we had also devised a special questionnaire in order to propose and to work out by experts. The experts were specialists with practical experience in pharmacy and sufficient experience in the field of innovation and science: scientific staff of Higher Educational Establishments, research organizations, heads and specialists of pharmaceutical companies (FC), patent and licensing services, etc.
Results. A detailed analysis, which was conducted by competent experts, has established the main problems of intellectual resources management in the domestic pharmacy at the macro, industry and micro levels. It has proved that at macro and industry level, implementation of the state innovation policy in order to attract foreign and domestic investments for the financing of fundamental research is necessary to obtaining new scientific results, the creation of competitive drugs, as well as the development of concepts and programs are aimed at on the development and regulation of innovation in pharmacy; the use of modern intellectual resources management strategies that are widely used by foreign pharmaceutical companies (the creation of biopharmaceutical clusters, strategic alliances for the implementation of high-value innovation projects, the development of public-private partnerships, etc.). At the micro level strategic directions in the field of intellectual resources management have established: increase of innovation activities in universities, research institutions, pharmaceutical companies; introduction of modern mechanisms of intellectual activity commercialization; formation of intangible assets register as a strategic resource for increasing the competitiveness of the organization.
Conclusions. Using cause-and-effect relationship Ishikawa diagram the potential reserves of intellectual resources (structural, human, market) management in pharmacy have generalized. Each of the presented reserves performs certain tasks and only in aggregate they provide the main goal – improving the intellectual resources management in pharmacy.
References
Avdeichik, O. V., Nekhorosheva, L. N. (2015). Traektoriia nauki, 5, 1–17.
KyivPharma–2017. Yak dosiahty evropeiskoho rіvnia farmatsevtychnoi osvіty, nauky ta bіznesu v Ukrainі? (2017). Ezhenedelnik Apteka, 1120 (49). Available at: http://www.apteka.ua/article/438539
3. Farmatsiia XXI stolittia: tendentsii ta perspektyvy. (2016). Kharkiv: NUPh,1 , 458.
Gosudarstvenno–chastnoe partnerstvo v sfere zdravookhraneniia. Mezhdunarodnyi opyt. (2017) Ezhenedelnik Apteka, 1104 (33). Available at: http://www.apteka.ua/article/423444
Krykavskyi, Ye. V., Pokhylchenko, O. A. (2011) Biznes–inform, 11, 4–7.
Chowdhury, F., Williams, A. (2016). Transfer from research/academia to clinical/regulated. Bioanalysis, 8 (20), 2169–2176. doi: 10.4155/bio–2016–4994
Fernald, K. D., Pennings, H. P. (2017). The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms’ innovation performance. PLoS One, 12 (2), e0172488. doi: 10.1371/journal.pone.0172488
Giannuzzi, V., Conte, R., Landi, A., Ottomano, S. A., Bonifazi, D., Baiardi, P., Ceci, A. (2017). Orphan medicinal products in Europe and United Statesto cover needs of patients with rare diseases: an increased common effort is to be foreseen. Orphanet Journal of Rare Diseases, 12 (1). doi: 10.1186/s13023–017–0617–1
Ravi, H. M., Dilip, G. (2015). Regulatory exclusivity strategies: further protection for pharmaceuticals in US, Europe and Japan. World journal of pharmacy and pharmaceutical sciences, 4, 971–992.
Maksimova, L. V. (2011). Meditcinskie tekhnologii. Otcenka i vybor, 1, 83–90.
Downloads
Published
Issue
Section
License
Copyright (c) 2018 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
